Nevertheless, we note that recent US-based cohort studies that have identified no difference in thrombosis risk between tofacitinib and TNF-inhibitors44–46, thereby suggesting that much of the observed risk seen in pharmacovigilance studies6,47 may be due to underlying risk factors rather than a drug effect. Here, TNF is linked to Venous thrombosis.